Spark Therapeutics (ONCE) Misses Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Spark Therapeutics (ONCE) Misses Q2 EPS by 7c

Spark Therapeutics Reports Second Quarter 2016 Financial Results and Recent Business Highlights

August 10, 2016 7:30 AM EDT

Updated timing of the completed BLA submission for voretigene neparvovec

Earlier today, released additional positive data from the pivotal Phase 3 trial of voretigene neparvovec

Reported positive preliminary safety and efficacy from the Phase 1/2 clinical trial of SPK-9001 in hemophilia

PHILADELPHIA, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE) today announced financial results for the quarter ended June 30, 2016 and updated investors on its progress.

During the last several months, we have made significant progress advancing our clinical portfolio of AAV gene therapy... More